Results 41 to 50 of about 4,485 (161)
All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine. [PDF]
PLoS ONE, 2016 BACKGROUND:Insulin therapy in type 2 diabetes may increase mortality and cancer incidence, but the impact of different types of basal insulins on these endpoints is unclear.
Arto Y Strandberg +5 more
doaj +1 more source
Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers
Advanced Functional Materials, Volume 36, Issue 44, 1 June 2026.A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley +1 more source
Detemir insulin for the treatment of diabetes mellitus in dogs
, 2015 Objective-To investigate the effects of insulin detemir in dogs with diabetes mellitus. Design-Prospective, uncontrolled clinical trial. Animals-10 client-owned dogs with naturally occurring diabetes mellitus.
Fracassi, F +5 more
core +2 more sources
Advanced Science, Volume 13, Issue 36, 29 June 2026.ABSTRACT The human body functions as a natural reactor for a vast network of chemical and biological reactions and physical interactions among small molecules, proteins, cells, and numerous other components. These reactions/interactions are essential for maintaining normal physiological functions.
Yuhao Cai, Chao Zhao
wiley +1 more source
Economic analysis of Lixisenatide in Diabetes Mellitus Type 2
Качественная клиническая практика, 2018 Usage of glucagon like peptide-1 receptors’ agonists (aGLP-1) is a new step in the treatment of Diabetes Mellitus Type 2 (DM 2). General attractive effects are positive effect on bodyweight, lower risk of hypoglycemia, compliance and possibility of ...
A. S. Kolbin +5 more
doaj
Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial. [PDF]
PLoS ONE, 2018 BACKGROUND:Despite their widespread use in this population, data on the pharmacodynamic (PD) properties of the insulin analogs detemir and glargine in severely obese patients with type 2 diabetes are lacking.
Stefan Bilz +5 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1476-1484, June 2026.In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono +10 more
wiley +1 more source
Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10. [PDF]
PLoS ONE, 2012 AIMS/HYPOTHESIS: There is controversy with respect to molecular characteristics of insulin analogues. We report a series of experiments forming a comprehensive characterisation of the long acting insulin analogues, glargine and detemir, in comparison ...
Bo F Hansen +6 more
doaj +1 more source
Pediatric Allergy and Immunology, Volume 37, Issue 6, June 2026.Maternal diabetes impairs fetal lung maturation, creating subclinical respiratory risks at birth. The study compared 37 newborns of diabetic mothers against 40 healthy controls using cord blood analysis and tidal breath measurements. Results showed elevated leptin alongside decreased ghrelin and adiponectin levels.
Simge Atar Bese +9 more
wiley +1 more source
Salud Uninorte, 2014 Objetivo: Analizar la costo-efectividad del uso de Detemir frente a otras insulinas (Glargine e NPH) para tratamiento de diabetes tipo 2 en Colombia. Métodos: Mediante un modelo de Markov se analizó la costo-efectividad desde la perspectiva del tercero ...
Martín Romero Prada +3 more
doaj